A Phase Ib, Multi-center, Open-label, Dose-escalation Study of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 Administered Orally in Patients With Myelofibrosis

Trial Profile

A Phase Ib, Multi-center, Open-label, Dose-escalation Study of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 Administered Orally in Patients With Myelofibrosis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs PIM 447 (Primary) ; Ribociclib; Ruxolitinib
  • Indications Myelofibrosis
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 21 Feb 2018 Planned End Date changed from 26 Jul 2018 to 31 Dec 2018.
    • 21 Feb 2018 Planned primary completion date changed from 29 Dec 2017 to 31 Dec 2018.
    • 21 Feb 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top